220 related articles for article (PubMed ID: 25466504)
1. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.
Lartigue L; Neuville A; Lagarde P; Brulard C; Rutkowski P; Dei Tos P; Wardelmann E; Debiec-Rychter M; Italiano A; Coindre JM; Chibon F
Eur J Cancer; 2015 Jan; 51(1):75-83. PubMed ID: 25466504
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Li J; Dang YZ; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):216-20. PubMed ID: 23536338
[TBL] [Abstract][Full Text] [Related]
3. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors.
Lagarde P; Pérot G; Kauffmann A; Brulard C; Dapremont V; Hostein I; Neuville A; Wozniak A; Sciot R; Schöffski P; Aurias A; Coindre JM; Debiec-Rychter M; Chibon F
Clin Cancer Res; 2012 Feb; 18(3):826-38. PubMed ID: 22167411
[TBL] [Abstract][Full Text] [Related]
4. Managing GIST in the imatinib era: optimization of adjuvant therapy.
Trent JC; Subramanian MP
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1445-59. PubMed ID: 25340579
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.
Lee CK; Goldstein D; Gibbs E; Joensuu H; Zalcberg J; Verweij J; Casali PG; Maki RG; Cioffi A; Mcarthur G; Lord SJ; Yip D; Kanjanapan Y; Rutkowski P
Eur J Cancer; 2015 May; 51(7):852-60. PubMed ID: 25801699
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
Schindler CG; Armbrust T; Gunawan B; Langer C; Füzesi L; Ramadori G
Z Gastroenterol; 2005 Mar; 43(3):267-73. PubMed ID: 15765299
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
Joensuu H
Drugs; 2012 Oct; 72(15):1953-63. PubMed ID: 22994537
[TBL] [Abstract][Full Text] [Related]
8. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
10. New fronts in the adjuvant treatment of GIST.
Reichardt P; Joensuu H; Blay JY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
[TBL] [Abstract][Full Text] [Related]
11. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.
Gronchi A
Eur J Cancer; 2013 Mar; 49(4):884-92. PubMed ID: 23206668
[TBL] [Abstract][Full Text] [Related]
12. [Gastrointestinal stromal tumour: our experience].
Versaci A; Macrì A; Ieni A; Terranova M; Leonello G; Saladino E; Speciale G; Famulari C
Chir Ital; 2009; 61(2):161-9. PubMed ID: 19536989
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of imatinib for treatment of metastatic GIST.
Patel S
Cancer Chemother Pharmacol; 2013 Aug; 72(2):277-86. PubMed ID: 23503753
[TBL] [Abstract][Full Text] [Related]
14. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal stromal tumor: 15-years' experience in a single center.
Wang M; Xu J; Zhang Y; Tu L; Qiu WQ; Wang CJ; Shen YY; Liu Q; Cao H
BMC Surg; 2014 Nov; 14():93. PubMed ID: 25403624
[TBL] [Abstract][Full Text] [Related]
16. Genomic Grade Index predicts postoperative clinical outcome of GIST.
Bertucci F; Finetti P; Ostrowski J; Kim WK; Kim H; Pantaleo MA; Astolfi A; Polkowski M; Birnbaum D
Br J Cancer; 2012 Oct; 107(8):1433-41. PubMed ID: 22929880
[TBL] [Abstract][Full Text] [Related]
17. Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
Gasparotto D; Miolo G; Torrisi E; Canzonieri V; Bertola G; Libra M; Marzotto A; Maestro R; Buonadonna A
Int J Colorectal Dis; 2014 May; 29(5):639-40. PubMed ID: 24525699
[No Abstract] [Full Text] [Related]
18. Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned.
Cheng CT; Tsai CY; Yeh CN; Chiang KC; Chen YY; Wang SY; Chen TW; Tseng JH; Jung SM; Chen TC; Yeh TS
Anticancer Res; 2014 Nov; 34(11):6617-25. PubMed ID: 25368266
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG
BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.
Li Y; Meng X
Ann R Coll Surg Engl; 2015 Apr; 97(3):215-20. PubMed ID: 26263807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
